FDA-cleared AI morphology systems displacing microscopy review
#1CellaVision DM96/DM1200 systems are now deployed in hundreds of clinical labs globally, pre-classifying peripheral blood smear differentials using deep convolutional neural networks trained on millions of annotated cells — reducing manual classification time by 50-70% and eliminating the need for routine manual microscopy in most cases. Scopio Labs published validation data in 2022-2023 demonstrating whole-slide digital PBS review with AI differential performance statistically non-inferior to senior technicians on standard WBC classification. Multiple companies (Medica Corporation, LBT Innovations, Motic) are pursuing FDA 510(k) clearances for expanded AI morphology applications including body fluids and urine sediment, with the regulatory pathway now well-established.